The number of children and adolescents living with life-limiting conditions and potentially in need for specialised paediatric palliative care (SPPC) is rising. Ideally, a specialised multiprofessional team responds to the complex healthcare needs of children and their families. The questions of, how SPPC is beneficial, for whom, and under what circumstances, remain largely unanswered in the current literature. This study’s overall target is to evaluate the effectiveness of a SPPC programme in Switzerland with respect to its potential to improve patient-, family-, health professional-, and healthcare-related outcomes.
This comparative effectiveness study applies a quasi-experimental design exploring the effectiveness of SPPC as a complex intervention at one treatment site in comparison with routine care provided in a generalised PPC environment at three comparison sites. As the key goal of palliative care, quality of life - assessed at the level of the patient-, the family- and the healthcare professional - will be the main outcome of this comparative effectiveness research. Other clinical, service, and economic outcomes will include patient symptom severity and distress, parental grief processes, healthcare resource utilisation and costs, direct and indirect health-related expenditure, place of death, and introduction of SPPC. Data will be mainly collected through questionnaire surveys and chart analysis.
The need for SPPC has been demonstrated through numerous epidemiological and observational studies. However, in a healthcare environment focused on curative treatment and struggling with limited resources, the lack of evidence contributes to a lack of acceptance and financing of SPPC which is a major barrier against its sustainability. This study will contribute to current knowledge by reporting individual and child level outcomes at the family level and by collecting detailed contextual information on healthcare provision. We hope that the results of this study can help guiding the expansion and sustainability of SPPC and improve the quality of care for children with life-limiting conditions and their families internationally.
Registered prospectively on ClinicalTrials.gov on January 22, 2020. NCT04236180
Following ongoing medical advances and improved diagnosis and coding, the number of children and adolescents living with life-limiting conditions is rising drastically . Estimates from the United Kingdom showed a prevalence of 26.7 per 10,000 children aged 0–19 years in 2000/2001, and a prevalence of 66.4 per 10,000 in 2017/2018 . Many of these children and adolescents need palliative care (PC) services. A new consensus describes PC as “the active holistic care of individuals across all ages with serious health related suffering because of severe illness and especially of those near the end of life. It aims to improve the quality of life of patients, their families, and their caregivers.” (, p. 761). As a special and highly complex subfield of PC, paediatric PC (PPC) is concerned with the support and involvement of the entire family, and aims to impact the patient-, family and health system levels. Ideally, to meet the complex healthcare needs of children and their families, a specialised multiprofessional team will be available, i.e. PPC services are offered by healthcare professionals specifically trained and working in PPC in the context of a dedicated programme setting .
Specialised PPC (SPPC) programmes most commonly offer a consultative model of care, i.e. by a specialised multiprofessional PPC team that either provides direct patient care and family support that goes beyond the affected child’s eventual death or provides support and advice to the child’s primary care team in and outside of the hospital . In such a setup, medical specialists (mainly physicians), e.g. neurologists or oncologists refer their patients and families in need. Referrals are mainly driven by symptom burden and the burden of the child’s condition on the entire family. However, the referral practices also depend on personal attitudes and motivation of the referrers from the medical specialties towards SPPC. Furthermore, the referrer’s perception of evidence supporting SPPC can be considered as a contextual factor influencing referral practices  and it is well recognised that compelling scientific evidence on the effectiveness of SPPC is scarce [6,7,8].
State of research
The question of whether PC in general is associated with improved patient and caregiver outcomes has been studied and summarised in a meta-analysis of 43 randomised controlled trials with data on 12′731 adult patients . PC interventions were associated with improvements in patient quality of life (QOL) and symptom burden, however, results regarding caregiver outcomes were inconsistent . In PPC, patient-reported outcome assessments are not normally feasible due to the patient’s age or cognitive state. Therefore, in paediatric research, proxy reports from parents are commonly used . A systematic review including eight observational studies found improved QoL in children and family members, improved symptom control, and a positive impact on place of care and family support . The burdens on family members are substantial. Investigating the impact of chronic health conditions on siblings psychological functioning and well-being, Vermaes et al. noted, that the siblings of children with life-threatening conditions appeared especially prone to psychological problems . A recent scoping review, including 34 studies concluded that the experiences these siblings make, impact the way they cope with stress . We found no studies about the influence of SPPC services on the QOL of these siblings.
For healthcare professionals (HCPs), providing compassionate care for children with life-limiting conditions and their families is emotionally demanding. High expectations, lack of support and a sense of inadequate preparation, representing demands from the health care system, can lead to stress in care personnel . One purpose of a consultative SPPC service model is to provide support and advice to each child’s/family’s primary care team, which might ease the care burden and positively influence the QOL of healthcare professionals not specialised in PPC. In a US study of 314 diverse HCPs, 39% were gaged at risk for compassion fatigue (CF), a construct within professional QOL linked to impaired quality of care provision [14, 15].
More evidence related to improved process outcomes at the service level and healthcare resource utilisation is available regarding children/families receiving SPPC. A recent systematic review including 14 cohort studies and one case series found, that the receipt of PPC was associated with a decrease in intensive care use and high-intensity end-of-life care. Regarding hospital admissions, length of stay in hospital, resuscitation orders, and the proportion of hospital and home deaths results were less conclusive . Evidence on healthcare resource utilisation and costs among children, who had accessed a PPC programme versus those, who had not, was summarised in a systematic review . Children enrolled in PPC had fewer hospital admissions, with most studies also showing shorter hospital stays. Conflicting results arose regarding the proportion of patients who received critical care, and calculations of overall healthcare costs were inconclusive . Lower medical costs among PPC recipients through the reduction of healthcare utilisation, however, were recorded in more recent studies [18, 19].
The effectiveness of SPPC as a complex intervention is potentially influenced by many accompanying factors through mechanisms which are not well understood. Important potential mediators of the receipt of SPPC, e.g., the family’s adaptability, should be considered. Based on McCubbin & McCubbin’s resilience model of family stress, adjustment and adaptation, a positive relationship has been described between the family’s adaptation and the family system, i.e., coherence and family hardiness . Associated with adaptation and considered as central to successful coping with family stressors is the construct of sense of coherence. This refers to an orientation between family members, that makes their reactions to internal and external stimuli structured and predictable, providing resistance resources for handling stimuli, and fostering a sense that life’s challenges are meaningful . Family hardiness has been described as a family resource and acknowledged as a mediator in the relationship between stress and illness. As such it has also been related to family members’ health and QOL .
As more and more countries have recognised the need for SPPC at the policy level, the international development and implementation of PPC programmes have skyrocketed. However, many of those programmes struggle with the transition into routine in- and outside hospital care and therefore sustainability . The question, of how SPPC is beneficial for whom and under what circumstances, remains largely unanswered as validation of innovative care programmes in controlled studies is lacking . Determining clinical effectiveness will require prospective studies using comparison groups to establish the relationship between the receipt of SPPC and selected outcomes on the client and service levels . Additionally, the question of when to initiate SPPC, and the outcomes of early vs. late introduction of SPPC have never been compared, a comparison of the two has been judged a priority in PPC research . Reporting on outcome metrics at the family level and addressing contextual information on healthcare provision has the potential to guide the expansion and sustainability of services and improve the quality of care for children with life-limiting conditions and their families internationally.
The SPhAERA study’s overall target is to evaluate the effectiveness of SPPC and to report on its potential to improve patient-, family-, health professional-, and healthcare-related outcomes. Specifically,
to explore how SPPC influences the QOL of patients (including their symptom severity and distress), parents and siblings (including grief processes);
to explore how the availability of an SPPC team influences the QOL of healthcare professionals not specialised in PPC;
to determine whether the provision of SPPC reduces the utilisation of healthcare resources and costs;
to determine whether the provision of SPPC reduces direct and indirect health-related costs for families; and
to evaluate the introduction of SPPC and validation of the Paediatric Palliative Screening Scale (PaPaS-Scale) .
Design and setting
This study applies a quasi-experimental design within the framework of comparative effectiveness research, exploring the effectiveness of SPPC as a complex intervention in comparison with routine care provided in a non-specialised PPC environment. The study takes place at four study sites: the largest Swiss University Children’s Hospital with a longstanding established dedicated SPPC programme serves as the intervention site, two other Swiss university children’s hospitals and a Cantonal children’s hospital providing general PPC and are just developing SPPC comprise the comparison sites. Recruitment took place between November 2019 and May 2022, and the longitudinal data collection is ongoing until May 2023. An overview of the study’s setup, timeline and outcomes is provided in Fig. 1.
Participants and recruitment
Patients and families
Children suffering from a life-limiting condition and potentially in need of SPPC, their parents and siblings, as applicable, were eligible to enter the study under the following inclusion criteria: 1) children, aged 0–18 years; parents (mothers and/or fathers) of included children; 2) siblings, aged 8–18 years, of included families; 3) proficiency in German or French language. Neonates with medical complications due to prematurity and/or birth complications and treated in a neonatal intensive care unit and patients enrolled in the SPPC programme with an expected life expectancy of < 48 h were excluded due to limited exposure time. Additionally, children and their families under child protection regulations were not eligible.
For the intervention site, all children entering the SPPC programme, after referral by a member of the frontline care team (usually a physician), were prospectively and consecutively screened for eligibility and invited for study participation. Recruitment was then performed by a member of the SPPC team within the first 2 weeks of SPPC initiation.
For the comparison sites, recruitment started in February 2020 and was performed by specialists of various medical disciplines, e.g. neurology or oncology after evaluating the potential need for SPPC of their patients. This need was defined per indication criteria of the SPPC programme at the intervention site and read as follows: 1) increase in (unplanned) hospital admissions during the last months; 2) adverse medical events from which the child is not recovering completely; 3) increasing symptom burden; unsatisfactory response to treatments; 4) conflicting treatment goals; 5) estimated life expectancy less than 6–12 months; 6) patient’s/parents’ wish for PC support .
Healthcare professionals (HCPs)
All HCPs of the following professions working at the study sites or in collaboration with them and involved in the care of the population under study were invited for study participation: physicians, registered nurses, health care assistants, psychologists, social workers, physical therapists, occupational therapists, nutritionists, pastoral workers, logo therapists, social pedagogues, remedial teachers and certified social care workers. To ensure their involvement in PPC, the following inclusion criteria were defined: 1) having cared for patients and their families in the PC phase during a minimum of ten shifts (day/late-shift) or ten consultations and/or 2) having cared for a minimum of two patients in the end-of-life phase and their families or after the death of the child; 3) employment in their institution for a minimum of 3 months. Members of the SPPC team at the intervention site were excluded due to their specialisation and dedicated SPPC activities including intervention provision.
Recruitment took place in two cycles: first cycle beginning of 2021 and second cycle beginning of 2022. All HCPs were invited via the written study information which they received through a local coordinator at their institution. The HCPs were instructed to autonomously check their eligibility for study participation based on the criteria listed above.
Intervention and comparison
The service of a SPPC team is considered as a complex intervention with components on various levels and of variable dosing, based on the needs of each individual patient and her/his family. All services provided to patients/families by a member of the multiprofessional SPPC team at the University Children’s Hospital in Zurich are considered as study intervention. This includes direct medical, nursing, social, and psychological and spiritual consultations of the patient/family, as well as patient−/family-related consultation of the frontline care team. Bereavement support, as integrated part of SPPC is routinely offered at the individual or group level as appropriate for parents and siblings. The programme at the intervention site offers full 24/7 services from the SPPC team’s physicians, nurses and psychologists and includes home visits.
For patients/families in the comparison group (Aarau, Basel, Berne) routine care is provided as per established paediatric standards in a generalised PPC environment (provided by disease specific specialists with some PPC training ) already in place at all study sites. In all of the three comparison sites a PPC team is available since 2019/2020. However, these developing teams differ on the level of capacity, i.e. few human resources and mostly professionals with basic training and experience in PPC without being fully engaged in PPC, no 24/7 coverage, and limited psychologist and bereavement support.
Assignment to study groups will happen naturally, determined through the recruiting study sites. As this study is conducted in a natural environment with continuous development of care practices, adaptations of care structures and processes at all study sites are possible and probable during the duration of the study. No restraints of this natural evolution will be superimposed by the study. Care context is assessed on yearly basis in all four participating study sites, described and used as instrumental variables estimation as applicable.
Outcomes and procedures
Improving and maintaining QOL is the core intention of PC and is the main outcome of this comparative effectiveness study. For an overview of the study’s setup and timeline, outcomes and measurements, and assessment timepoints see Fig. 1 and Tables 1 and 2.
Patients and families
Since a large proportion of the study population is young or cognitively impaired, we defined caregiver QOL as the primary outcome. Each participating patient/family is followed for a maximum time of 1 year as long as the child is alive. Assessment timepoints are dynamic, starting with two bi-weekly assessments, followed by four monthly assessments and three-monthly after that. For families, who lose their child during the study, bereavement follow-up continues for another year with four assessments. All outcomes on the family level are assessed as surveys with self-reported and validated questionnaires on paper. Questionnaires are distributed in the hospital or sent home by the study team in case the child is at home at the time of a study assessment. Outcomes on the patient level are assessed as proxy measures through the parents, unless the patient is capable to report her−/himself. Siblings’ QOL is only assessed, if they are able to self-report.
Service outcomes are assessed through the collection of routine data via chart review at assessment timepoints. This includes patient-specific information related to healthcare resource utilization, e.g. hospital admissions and length of stays, procedures, and diagnostic information and date of death. Economic outcomes are assessed through queries for each patient for costs on the healthcare system level (hospitals, formal payers) and through self-reported direct and indirect health-related expenditure data (questionnaire) from participating families.
HCPs’ professional QOL was retrospectively assessed for 1 year back after the first and second study year. All HCPs who returned their informed consent received the questionnaire as a hard copy through institutional or postal mail.
All study participants are withdrawn from the study in the case of consent withdrawal or relevant non-adherence to study procedures, i.e. failure to complete questionnaires. No specific follow-up beyond the date of withdrawal/discontinuation is performed and no more data is collected. All data collected up to study withdrawal/discontinuation will be considered for analysis.
Sample size and statistical analyses
We hypothesise that SPPC positively influences the QOL of the caring parents. The null hypothesis is that QOL does not differ between parents of patients in the SPPC programme and the comparison group. The sample size (number of paediatric patients) was calculated to be able to show a difference of 1 point in the QOLLTI-F score  1 month after study inclusion. The calculations are based on an expected mean QOLLTI-F of 5.5 (on a scale from 0 to 10) and an expected standard deviation of the QOLLTI-F score of 1.7, as reported in Cohen et al. . Note that similar values of mean ± SD, i.e., 5.8 ± 1, were observed by Groh et al. .
Sample size was calculated using a resampling method. Each sample size, n i = 1,...,41 = 10, ..., 250, was evaluated by simulating R = 499 times the QOLLTI-F of ni individual pairs of care giving parents from a multivariate normal distribution, using a correlation of 0.8 between parents of the same patient. For each sample size ni, half of the patients were allocated to the SPPC group and comparison group, with mean QOLLTI-F of 6 and 5, respectively, and a (within group) standard deviation of 1.7. Assuming that only one parent participates in the study for 30% of the patients, this proportion of simulated QOLLTI-F scores for the second parent was omitted, resulting in simulated QOLLTI-F scores for a pair of parents for 70% of the patients, and for only one parent for the remaining 30% of patients. The difference in QOLLTI-F between parents of SPPC vs. comparison patients was then estimated with a linear mixed-effects model with group (SPPC vs. comparison) as fixed factor, modelling a random intercept per patient (to account for the non-independence of parents from the same patient). Sample size was set to ensure at least a power, 1 – β, of 0.8 at a significance level, α, of 0.05.
For this study, a total of 98 paediatric patients should be recruited (i.e., 49 from the SPPC programme and 49 for comparison) to ensure a total of 98 evaluable pairs of care giving parents, considering a drop-out rate (i.e., proportion of patients who died or withdrew informed consent before QOLLTI-F could be assessed at least once) of 10%. Sample size was estimated using R (Version 3.5.0) , using the R packages nlme  and sse .
Primary and secondary analyses
The primary outcome QOLLTI-F of the care-giving parents 1 month after study inclusion will be analysed by a linear mixed-effects model with QOLLTI-F at baseline and group (SPPC vs. comparison) as fixed effects. A random intercept will be modelled per patient (to account for the non-independence of parents from the same patient). In addition, all measurements of QOLLTI-F taken at different follow-up visits will be analysed by a linear mixed-effects model as above, but with an additional random intercept per parent (to additionally account for the non-independence of multiple measurements per parent).
To adjust the effect size estimate for SPPC vs. comparison for potential confounders, we will use propensity score weighting. Potential confounders were already identified and include characteristics of the patient (diagnosis, age, sex), disease duration, family system (sense of coherence, family hardiness), sociodemographic variables of the family (e.g. parental living situation, family income), and contextual information (e.g. study site characteristics). As a sensitivity analysis, we will add the most important confounders as covariates in the statistical models (analysis of covariance approach).
Secondary endpoints will be analysed by linear mixed-effects models or generalised linear mixed-effects models (in case of non-normal error distribution). Normal linear models or generalised linear models may be used for secondary outcomes measured only once per patient. Sensitivity analyses will be performed as applicable and appropriate.
Missing measurements of the primary outcome, QOLLTI-F at 1 month, will be multiply imputed, based on measurements taken at 2 weeks (first follow-up measurement) and available patient characteristics.
Data management, monitoring and risks
The sponsor-investigator is implementing and maintaining quality assurance and quality control systems to ensure that the study is conducted and data are generated, documented (record), and reported in compliance with the protocol, good clinical practice, and applicable regulatory requirement(s). Data extracted from the patient charts will be entered into an internet-based secure data base secuTrial® developed in agreement to the Good Clinical Practice guidelines provided by the Clinical Trials Centre Zurich. Person data will be pseudonomised through secuTrial®. Local coordinators will be assigned to assist with and facilitate logistics concerning the availability of medical charts and workspace in each participating study site. Data collectors will receive instructions and training before the start of data collection to assure and enhance data quality. Furthermore about 5% of the charts will be randomly chosen and data will be collected by two different people for quality checking.
A quality assurance audit/inspection of this study may be conducted by the competent ethics committee. The quality assurance auditor/inspector will have access to all medical records, the investigator’s study related files and correspondence, and the informed consent documentation that is relevant to this clinical study. We consider the risk for participants in this study as minimal. Allocation to intervention and comparison groups is determined by the natural environment of the four study sites’ care services.
This study evaluates the effectiveness of SPPC and its impact on patient-, family-, health professional-, and healthcare-related outcomes. The study will contribute to current knowledge by providing relevant outcome data based on the assessment of SPPC services within a comparative effectiveness research framework. Reporting on outcome metrics at the family level and providing detailed contextual information on healthcare provision has the potential to guide the expansion and sustainability of services and improve the quality of care for children with life-limiting conditions and their families internationally.
Determining clinical effectiveness will require prospective studies using comparison groups to establish the relationship between the receipt of SPPC and selected outcomes on the client and service levels . However, the classical randomised controlled trial study design with its origin in establishing the efficacy of new drugs under controlled situations falls short in evaluating the effectiveness of a complex intervention in a real-world setting. Effectiveness research broadens the design options for evaluating interventions by possibly loosening up some of the rigorous control measures mandatory in a randomised controlled trial and therefore trading off strong internal validity in favour of generalisability (external validity) . The consequence of less rigorous controls is an increased risk of confounding, which may limit causal interpretation of the study results.
Dealing with potential imbalance between intervention and comparison group will likely be this study’s greatest challenge. We will take all possible and reasonable measures, e.g. propensity scoring, multilevel modelling to ensure justified group comparisons and interpretation. The study’s rich longitudinal data over a period of approximately 1 year will allow a unique reporting on courses of illness of the child, of the QOL of close family members and the family’s financial hardships.
A variety of outcome indicators were used to assess the impact of SPPC so far. Widger et al. found 82 different indicators reported through 46 studies. Among this large number, indicators such as location of death, length of stay in hospital and number of hospital admissions, only 22 indicators were reported in at least two studies . Many of these so far used indicators are also assessed in our study. Others, such as our main outcome of QOL on different levels are less investigated, limiting comparability with our study results.
The main results of this study will be communicated to patients, their family, and the involved healthcare professionals by a letter in lay language. The study group will make every endeavour to publish the data in peer-reviewed journals and we are convinced that this study’s comparative effectiveness and longitudinal approach will generate new meaningful evidence to advance the field of PPC internationally.
Availability of data and materials
DISABKIDS Chronic Generic Measure
Family Hardiness Index
Family Sense of Coherence
Health Care Professional
Memorial Symptom Assessment Scale
Quality of Life
Quality of Life in Life Threatening Illness–Family Carer
Paediatric Palliative Screening Scale
Paediatric Palliative Care
Specialised Paediatric Palliative Care
The WHO Quality of Life
Fraser LK, Gibson-Smith D, Jarvis S, Norman P, Parslow RC. Estimating the current and future prevalence of life-limiting conditions in children in England. Palliat Med. 2021;35(9):1641–51.
Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4:50.
Downing J, Knapp C, Muckaden MA, Fowler-Kerry S, Marston J, Committee IS. Priorities for global research into children's palliative care: results of an international Delphi study. BMC Palliat Care. 2015;14:36.
Thienprayoon R, Jones E, Humphrey L, Ragsdale L, Williams C, Klick JC. The pediatric palliative improvement network: a national healthcare learning collaborative. J Pain Symptom Manag. 2022;63(1):131–9.
Feudtner C, Rosenberg AR, Boss RD, Wiener L, Lyon ME, Hinds PS, et al. Challenges and priorities for pediatric palliative care research in the U.S. and similar practice settings: report from a pediatric palliative care research network workshop. J Pain Symptom Manag. 2019;58(5):909–917.e903.
Kavalieratos D, Corbelli J, Zhang D, Dionne-Odom JN, Ernecoff NC, Hanmer J, et al. Association between palliative care and patient and caregiver outcomes: a systematic review and meta-analysis. JAMA. 2016;316(20):2104–14.
Tay J, Widger K, Stremler R. Self-reported experiences of siblings of children with life-threatening conditions: a scoping review. J Child Health Care. 2021:13674935211026113. https://doi.org/10.1177/13674935211026113.
Sinclair S, Raffin-Bouchal S, Venturato L, Mijovic-Kondejewski J, Smith-MacDonald L. Compassion fatigue: a meta-narrative review of the healthcare literature. Int J Nurs Stud. 2017;69:9–24.
Lin SC, Huang MC, Yasmara D, Wuu HL. Impact of palliative care on end-of-life care and place of death in children, adolescents, and young adults with life-limiting conditions: a systematic review. Palliat Support Care. 2021;19(4):488–500.
Conte T, Mitton C, Trenaman LM, Chavoshi N, Siden H. Effect of pediatric palliative care programs on health care resource utilization and costs among children with life-threatening conditions: a systematic review of comparative studies. CMAJ Open. 2015;3(1):E68–75.
Lysecki DL, Gupta S, Rapoport A, Rhodes E, Spruin S, Vadeboncoeur C, et al. Children’s health care utilization and cost in the last year of life: a cohort comparison with and without regional specialist pediatric palliative care. J Palliat Med. 2022;25(7):1031–40.
McCubbin MA, McCubbin HI. Families coping with illness: the resiliency model of family stress, adjustment and adaptation. In: Danielson CB, Hamel-Bissel B, Winstead-Fry P, editors. Families, health & illness: perspectives on coping and intervention. St. Louis: Mosby; 1989.
Osenga K, Postier A, Dreyfus J, Foster L, Teeple W, Friedrichsdorf SJ. A comparison of circumstances at the end of life in a hospital setting for children with palliative care involvement versus those without. J Pain Symptom Manag. 2016;52(5):673–80.
Bergstraesser E, Hain RD, Pereira JL. The development of an instrument that can identify children with palliative care needs: the Paediatric Palliative Screening Scale (PaPaS Scale): a qualitative study approach. BMC Palliat Care. 2013;12(1):20.
Baars RM, Atherton CI, Koopman HM, Bullinger M, Power M, group D. The European DISABKIDS project: development of seven condition-specific modules to measure health related quality of life in children and adolescents. Health Qual Life Outcomes. 2005;3:70.
Collins JJ, Byrnes ME, Dunkel IJ, Lapin J, Nadel T, Thaler HT, et al. The measurement of symptoms in children with cancer. J Pain Symptom Manag. 2000;19(5):363–77.
Collins JJ, Devine TD, Dick GS, Johnson EA, Kilham HA, Pinkerton CR, et al. The measurement of symptoms in young children with cancer: the validation of the memorial symptom assessment scale in children aged 7-12. J Pain Symptom Manag. 2002;23(1):10–6.
We would like to thank wholeheartedly Kerstin Birkeland-Ackermann for representing the study’s target population and providing valuable input concerning the feasibility of assessments. We also thank Dirk Smolinski, Lisette Paratore and the team at the Clinical Trials Center Zurich for their support in data management.
This research project has received grants from the following funding bodies: the Swiss Academy of Medical Sciences (No PC25/18); the Swiss Society of Pediatrics, together with the Swiss Research Network of Clinical Pediatric Hubs; the Kristian Gerhard Jebsen Foundation, and the UBS Optimus Foundation.
None of the funding bodies were involved in the design of the study and data collection.
Authors and Affiliations
Paediatric Palliative Care and Children’s Research Center CRC, University Children’s Hospital Zurich, Steinwiesstrasse 75, 8032, Zurich, Switzerland
Karin Zimmermann & Eva Bergstraesser
Department Public Health (DPH), Nursing Science, University of Basel, Bernoullistrasse 28, 4056, Basel, Switzerland
Karin Zimmermann, Michael Simon, Stefan Mitterer & Anne-Kathrin Gerber
Division of Pediatric Oncology – Hematology and Palliative Care, Kinderspital, Kantonsspital Aarau AG, Tellstrasse 25, 5001, Aarau, Switzerland
Department of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland
Department of Pediatrics, McMaster Children’s Hospital and University, Hamilton, Canada
Division of Pediatric Heamtology and Oncology, Paediatric Palliative Care, Children’s Hospital, Inselspital, Universitätsspital Bern, Freiburgstrasse 10, CH-3010, Bern, Switzerland
KZ and EB jointly designed the study. All authors contributed to the development and finalisation of the study plan. SVF conducted the power analysis and crafted the statistical content. KZ wrote the grant proposals, the protocol for ethics approval and this manuscript. SM registered the study on ClinicalTrials.gov. All authors critically read and revised the content of this manuscript and approved its final version.
The study was approved by the ethics committee Zurich as the leading ethics advisory body (BASEC-Nr. 2019–01170), and by the committees in Nordwest- und Zentralschweiz (for the sites Aarau and Basel), and Berne, and complies with the Swiss Federal act on research involving human beings. Substantial amendments (significant changes) are only implemented after approval of the ethics committees. All children (as applicable) and parents for this study were provided a child/parent information sheet and a child/parent consent form describing this study and providing sufficient information for children and parents to make an informed decision about their participation in this study.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Zimmermann, K., Simon, M., Scheinemann, K. et al. Specialised Paediatric PAlliativE CaRe: Assessing family, healthcare professionals and health system outcomes in a multi-site context of various care settings: SPhAERA study protocol.
BMC Palliat Care21, 188 (2022). https://doi.org/10.1186/s12904-022-01089-x